Company intelligence / Profile preview

Niowave

Lansing, Michigan, United States

Ownership: Private
Development stage: Other

Overview

Niowave manufactures medical and industrial radioisotopes, particularly actinium-225 (Ac-225) for cancer treatment. The company has been processing radium-226 since 2017 and actively producing Ac-225, with production capacity expected to exceed 5-10 Ci per year through partnership with QSA Global.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Chemicals & Materials

Partnerships

QSA Global (Partnership established in August 2024 to transfer Niowave's radium-226 processing technology to QSA and co-develop scalable radium purification process, with QSA commencing multi-year supply of purified Ra-226 to Niowave in early 2025)

Beyond the preview

Go deeper on Niowave.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niowave.

Explore the full profile